Zimbabwe is set to roll out a Shorter, Highly-effective, Oral Regimen for Rifampicin-resistant Tuberculosis (SHORRT therapy) which reduces the length of treatment for Multi-Drug Resistant Tuberculosis (MDR-TB) from nearly two years, to, nine to 12 months and brings a major improvement in treatment outcomes and qual